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A B S T R A C T
Purpose: Focal cortical dysplasia (FCD) type II is a frequent cause of medically intractable epilepsy. On
conventional MRI diagnosis may be difﬁcult. The purpose of our study was to assess the metabolic
characteristics of MRI-typical or neuropathologically conﬁrmed FCD II lesions at 3 T.
Methods: In a prospective study, 13 patients with drug-resistant epilepsy and MRI diagnosis of FCD II
(seven neuropathologically conﬁrmed) were investigated by single-volume proton magnetic resonance
spectroscopy (1H MRS). We performed an intra-individual comparison placing spectroscopic volumes of
interest in the lesion and in the apparently normal contralateral hemisphere. Spectroscopic results were
correlated with clinical data.
Results: Matched pair analysis revealed a signiﬁcant increase in absolute choline (Cho) concentration in
the lesion volume (+32%, p = 0.015) compared to the control volume. This increase was associated with a
signiﬁcant decrease in N-acetyl-aspartate (NAA) concentration (13%; p = 0.008). Mean myo-inositol
(Ins) levels were distinctly (+36%) but not signiﬁcantly (p = 0.051) elevated. Lesional creatine (Cr)
concentration correlated signiﬁcantly with the frequency of seizures (Spearman-Rho r = 0.898;
p = 0.002), while concentrations of NAA, Cho and Ins did not correlate with clinical or imaging
parameters.
Conclusion: MR spectroscopy revealed a characteristic metabolic pattern in FCD II lesions that helps to
distinguish normal from epileptogenic tissue.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Focal cortical dysplasia (FCD) type II is a frequent cause of drug-
resistant focal epilepsy [1]. It belongs to the group of malformationsAbbreviations: FCD, focal cortical dysplasia; 1H MRS, proton magnetic resonance
spectroscopy; VOI, volume of interest; NAA, N-acetyl-aspartate; Cho, choline
containing compounds; Ins, myo-inositol; Cr, total creatine; Glx, glutamate/
glutamine/GABA; Gln, glutamine.
* Corresponding author at: Department of Radiology, MRI, University of Bonn,
Sigmund-Freud-Strasse 25, 53127 Bonn, Germany. Tel.: +49 228 287 1 6505;
fax: +49 228 287 1 4321.
E-mail address: Henriette.Tschampa@ukb.uni-bonn.de (H.J. Tschampa).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.seizure.2015.08.008
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reof cortical development, characterized pathologically by the presence
of dysmorphic neurons in type IIa lesions and additionally by balloon
cells in type IIb [2–4]. The identiﬁcation of FCD by MR imaging allows
patients with pharmaco-resistant epilepsy to undergo resective
surgery, which yields rates of seizure-freedom of 70–80% [5–
7]. However, MRI characteristics of FCD are variable and the detection
of such a lesion remains challenging [7–10]. Moving to higher MR
ﬁeld strengths and with the help of computer-aided detection
systems such as morphometric MRI analysis [7,11], the identiﬁcation
of very small and sometimes questionable malformations of cortical
development becomes feasible.
Proton magnetic resonance spectroscopy (1H MRS) provides
quantitative information about the metabolic composition of brain
tissue in vivo. Previous reports on 1H MRS in focal cortical dysplasiaserved.
H.J. Tschampa et al. / Seizure 32 (2015) 23–2924have shown alterations of relative N-acetyl-aspartate (NAA) to
choline (Cho) and total creatine (Cr) ratios [12–17]. These valuable
studies, however, comprise very small and heterogeneous
populations and lack histological conﬁrmation of FCD in most
cases [12–19].
The identiﬁcation of a potential epileptogenic lesion in MRI is
crucial for patients with pharmaco-resistant epilepsy, as it
considerably improves the chances of postsurgical seizure-freedom.
In people without apparent MRI lesions, in turn, the identiﬁcation of
a pathology in brain biopsy predicts a better seizure outcome after
surgery [6]. Before performing invasive presurgical diagnostics in
suspected lesions or ‘‘MRI-negative’’ cases, an additional non-
invasive test is desirable to sustain the suspicion of FCD II. The aim of
the present study was to characterize the metabolic composition of
MR-tomographically typical and partly also neuropathologically
conﬁrmed FCDs using high-ﬁeld clinical 1H MRS.
2. Methods
2.1. Clinical data
We performed single-volume 1H MRS in 13 patients with
pharmaco-resistant epilepsy due to FCD as assessed by brain MRI.
All patients were in-patients of the Department of Epileptology at
the University of Bonn suffering from medically refractory epilepsy
who were evaluated for epilepsy surgery. The study protocol was
approved by the ethics committee of the University hospital and
patients or their caregivers gave written informed consent.
All studies were performed at an inter-ictal state, which was
determined by clinical observation, or in cases of auras, by self-
reports. Patients were receiving their standard regimen of antiepi-
leptic drugs.
To date, in seven patients surgery was performed. In three cases
FCD IIa and in four patients FCD IIb according to Palmini and Lu¨ders
[2] was conﬁrmed histologically. In one of the remaining patients,
FCD was located in the Broca area according to intralesionally
implanted electrodes, so that surgery was not possible, and ﬁve
patients have declined surgery to date.
Clinical features such as the age at onset of seizures, the seizure
frequency, the neuropathological diagnosis and the clinical
outcome were assessed (see Table 1).Table 1
Patients characteristics including clinical data, MRI, histology, and clinical outcome.





1 0.3/f 0.083 10 Lar
2 19/f 10 2 Lar
3 21/m 14 3 Sm
4 5/f 0.58 5 Lar
5 32/f 17 5 Sm
6 33/m 5 0.7 Sm
7 40/f 18 6.42 Me
8 34/f 10 2 Sm
9 45/m 24 0.42 Sm
10 51/f 37 6 Thr
lesi
11 60/f 8 0.57 Sm
12 74/m 6 5 Sm
13 13/f 12 8 Sm
a Lesion size is classiﬁed as:
Small (1 sulcus or 1 gyrus  adjacent sulci): Bottom of sulcus dysplasia, Crown of sulcus 
Medium (2 adjacent gyri).
Large (3 or more adjacent gyri).
b op., operation.2.2. MRI
All thirteen patients were examined at a 3 T clinical MR scanner
prior to 1H MRS. Routine epilepsy MRI was performed in all
patients [20]. The localisations of the spectroscopic target volumes
were planned in high resolution T1-weighted, T2-weighted and in
FLAIR images.
Conventional visual analysis of the structural MRI was done by
two neuroradiologists in consensus. A FCD II was diagnosed if the
following criteria were fulﬁlled: (1) blurring of grey and white
matter junction; (2) focal thickening of the cortex; (3) increased
signal on FLAIR/T2 in the subcortical white matter; (4) extension of
cortical tissue with increased signal from the surface to the
ventricle (transmantle dysplasia) or funnel-shaped extension of
subcortical high signal to the ventricle (bottom-of-sulcus dyspla-
sia) [21]. The size of the FCD was classiﬁed according to the
following scheme: Small: 1 sulcus or 1 gyrus  adjacent sulci,
including bottom-of-sulcus dysplasia, crown-of-gyrus dysplasia and
crown-of-gyrus & bottom-of-sulcus dysplasia; Medium: 2 adjacent
gyri; Large: 3 adjacent gyri.
The details on MRI analysis can be found in Table 1.
2.3. 1H MRS
Proton MRS was performed at a clinical 3 T system in all cases
(Achieva TX or Ingenia TX, Philips Healthcare, Best, the
Netherlands) using a SENSE receive-only 8-channel head coil
(twelve patients) or a transmit/receive head coil (one patient).
In each investigation, proton spectra were acquired in two
volumes of interest (VOI). The ﬁrst VOI was placed in the FCD
including the dysplastic cortex and the adjacent hyperintense area
in the subcortical white matter (Fig. 1). With exception of patient 4,
who had a very large lesion of the left frontal lobe (Fig. 2), the
spectroscopic volumes fully encompassed the FCDs. The mean
target volume size was 6.3 ml (range 4–12 ml). The volume was
planned as small as possible in order to exclude the adjacent
normal brain tissue from the FCD target volume. As a control
volume, an identically sized VOI was positioned in a mirror region
of normal appearing brain tissue in the contralateral hemisphere.
The MRS protocol included acquisition of water-suppressed
proton spectra with PRESS volume selection [22], TR/TE 2000/140
and 30 ms, and 128 signal averages. The TE of 140 ms was chosen diagnosisa Histology Outcome
ge FCD FCD IIa Seizure-free
ge FCD FCD IIa Seizure-free
all FCD IIb FCD IIa Seizure-free
ge FCD IIb FCD IIb Seizure-free
all FCD IIb FCD IIb Unknown
all FCD IIb FCD IIb Seizure-free
dium FCD IIb FCD IIb One seizure in 12
months not taking
medication
all FCD IIb No op.b (patient refused) Unknown
all FCD IIb No op.b (lesion in Broca area) Unknown
ee FCDs: Target
on large
No op.b (three FCDs) Unknown
all FCD IIb No op.b (patient refused) Unknown
all FCD IIb No op.b (patient refused) Unknown
all FCD IIb No op.b (patient refused) Unknown
dysplasia, crown and bottom of sulcus dysplasia.
Fig. 1. 51 y/o female patient (patient 10) with a history of daily complex focal seizures who had three FCDs but no cutanous signs of tuberous sclerosis, the largest FCD left
parietal. Upper part of the ﬁgure: Volumes of interest for 1H MRS were placed in the lesion (boxes in A–C) and in a control region in the contralateral hemisphere (see D–F).
Lower part of the ﬁgure: The MR spectra in the lesion (target volume, left side) show an increase in Cho (arrow pointing upwards) and a decrease in NAA (arrow pointing
downwards) in comparison to the control region (right side).
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caused by its anomalous J-coupling [23] was compensated by
increasing the refocusing pulse bandwidth.
Absolute quantiﬁcation of metabolite concentrations was
provided by non-water suppressed spectra with TR/TE 3500/
80 ms using the brain water signal as an internal reference.
Metabolite concentrations were corrected for partial volume
effects by bi-exponential ﬁtting of the T2-values and the relative
fractions of brain tissue water and CSF to an additional set of
7 unsuppressed spectra with TR/TE1–7 6000/35–800 ms. The wholeset of water-suppressed and unsuppressed spectra took about
15 min for each hemisphere. For reason of time, no spectra at TE
30 ms could be acquired for patients 3 and 7 so that for these
patients, we did not measure Ins values.
Relative and absolute concentrations of N-acetyl-aspartate
(NAA), total creatine (Cr), choline containing compounds (Cho),
myo-inositol (Ins), glutamine (Gln), glutamate/glutamine/GABA
(Glx), and lactate were determined after time-domain ﬁtting of the
acquired MR spectra using the AMARES algorithm of the MRUI
software package [24,25].
Fig. 2. 5 y/o female patient (patient 4) with a history of daily focal seizures, some with generalization since the age of 7 months. Upper part of the ﬁgure: A volume of interest
was placed in the large left frontal focal cortical dysplasia (A–C), and a control volume (D–F) in the contralateral hemisphere. Lower part of the ﬁgure: In the MR spectra of the
lesion (target volume, left side) a distinct increase in Cho and Ins and a strong reduction in NAA is observed as compared to the control volume (right side).
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Group analysis was performed using the Wilcoxon signed-rank
test for matched pairs and Spearman-Rho. P < 0.05 was considered
statistically signiﬁcant. Taking into account the regional differ-
ences of metabolite signals, only intra-individual statistical
comparisons of the absolute metabolite concentrations and the
metabolite ratios (metabolite signal with respect to that of Cr)
were calculated (Table 2). Absolute metabolite concentrations and
metabolite ratios were correlated with clinical data and imaging
data: seizure frequency per day, duration of epilepsy, post-




Matched pair-analysis of metabolite ratios showed a mean
relative increase in Cho/Cr of 26% (p = 0.012) and a reduction in
NAA/Cr of 21% (p = 0.001) in FCD lesion as compared to those
acquired from the control voxel in the contralateral hemisphere.
Absolute quantiﬁcation of metabolites revealed that these
Table 2
MR spectroscopy: Means and standard deviations of absolute and relative metabolite concentrations, and of percentage differences derived from lesional and contralateral
target volumes by matched pair analysis. Absolute concentrations in mmol/l brain tissue (bt), metabolite ratios NAA/Cr, Cho/Cr, and Ins/Cr calculated from spectra with TR/TE
2000/140 ms, [Ins] and Ins/Cr from spectra obtained with TR/TE 2000/30 ms.
[NAA] [Cho] [Cr] [Ins] NAA/Cr Cho/Cr Ins/Cr
mmol/l bt mmol/l bt mmol/l bt mmol/l bt
FCD lesion
Mean 10.01 2.57 9.36 5.82 1.46 1.17 0.70
SD 1.78 0.55 1.61 1.60 0.41 0.25 0.17
Contralateral
Mean 11.85 2.10 8.81 4.50 1.84 0.94 0.61
SD 1.24 0.46 1.30 1.11 0.31 0.20 0.13
p (matched-pairs) 0.008* 0.015* 0.110 0.051 0.00* 0.012* 0.248
% Differences FCD/contralateral
Mean 13 32 5 36 21 26 20
SD 8 35 9 58 13 31 43
* p-Value <0.05.
H.J. Tschampa et al. / Seizure 32 (2015) 23–29 27differences were caused by a signiﬁcant increase in Cho of 32%
(p = 0.015) and a signiﬁcant decrease in NAA concentration of 13%
(p = 0.008) in the lesions. No signiﬁcant differences were detected
for Ins/Cr, Gln/Cr and Glx/Cr metabolite ratios.
Although mean values of Cr and Ins concentration were higher
in the FCD lesions by about 5% and 36%, respectively, matched-pair
analysis showed no signiﬁcant differences of these metabolite
concentrations between FCD lesions and control regions
(p = 0.110 and p = 0.051), as differences were small for Cr andFig. 3. Scatterplot displays the relative differences of the metabolite ratios between the l
13 subjects. There was a decrease in relative NAA/Cr (upside down triangle) in all patient
Ins/Cr (rhombus) were ambiguous. No Ins measurements could be acquired for patienindividual ﬁndings were variable for Ins (see Table 2 and Fig. 3 for
details). Lactate was detected in FCD spectra of two patients
(patients 3 and 7).
Compared to the unaffected contralateral side, there was a
signiﬁcant positive correlation between the Cr concentration in the
FCD lesion, and the frequency of seizures per day (Spearman-Rho
r = 0.898; p = 0.002), while no signiﬁcant correlation was found
between lesional concentrations of NAA, Cho, and Ins and the
seizure frequency.esion and the normal appearing contralateral hemisphere (zero line) for each of the
s and a signiﬁcant increase in Cho/Cr in 10/13 FCDs (triangle). Individual ﬁndings for
ts 3 and 7 for reason of time.
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epilepsy, the post-operative seizure outcome and the size of the
lesion did not show any signiﬁcant association with metabolic
results.
4. Discussion
Using 3 T 1H MR spectroscopy, we found a signiﬁcant increase
in Cho and a reduction of NAA in patients with focal epilepsy due to
FCDs II. Our results are in line with previous reports on small
groups of FCD-patients investigated at 1.5 T [12,14,17,18] and 3 T
[16], and with a study at an experimental high ﬁeld 4.1 T MR
scanner [13]. Most of these studies described heterogeneous
populations including patients with malformations of cortical
development or low-grade brain tumours [19,26] with a few FCD
cases included [12–15,17,18,27]. While in the literature, most
authors report on a predominant NAA reduction [15–18,26], our
study is in accordance with Lundbom [12] where Cho was most
signiﬁcantly elevated. However, Cho increase and NAA decrease in
the FCDs appeared to be less pronounced than in low-grade brain
tumours [19,26]. Metabolic disturbances in cortical dysplasia are
mainly explained by disorganization of tissue architecture with
areas of immature and even undifferentiated cells [13,28]. FCD
spectra with low concentrations of NAA combined with elevated
Cho and Ins resemble normal brain spectra of young children
[29]. In contrast to that, in polymicrogyria the NAA/Cr ratio is
reported to be normal, which is explained by the fact that in
polymicrogyria the injury is postmigrational and the neurons are
mature [18]. Another explanation for the observed metabolic
abnormalities with decreased NAA and increased Cho is neuronal
cell loss in combination with gliosis as discussed in hippocampal
sclerosis [30–32]. Metabolic abnormalities were also described in
the contralateral hippocampus of people with temporal lobe
epilepsy due to unilateral hippocampal sclerosis and in people
with temporal lobe epilepsy in the absence of apparent MRI
lesions, albeit to a lesser extent [33,34]. Postoperative normaliza-
tion of metabolites on the non-operated side was observed
[28,33,34], which led to the assumption that the reversible NAA
reduction in the non-operated side is due to neuronal and glial
dysfunction and not to neuronal loss [28].
In our study, we used an intra-individual approach, placing a
voxel in the lesion and a control voxel in the normal appearing
contralateral side, as substantial regional [35] and age-dependent
[36] variations in healthy brain spectra but no signiﬁcant
differences between the two hemispheres [37] are known. Simone
et al. [15] also used the normal appearing contralateral side as the
control region and additionally compared their results with that of
healthy volunteers, while other authors only used healthy
volunteer brain metabolism for comparison to an FCD lesion
[12,13,17,26].
In our study the mean absolute concentration of Cr in the FCD
lesions did not differ signiﬁcantly from the concentration
measured in the contralateral control voxel (Table 2). However,
there was a signiﬁcant positive correlation between the Cr
concentration in the lesion and the frequency of seizures per
day. In that respect previous studies provided conﬂicting data.
While our results are in line with the work of Kuzniecky and
colleagues [13], other authors [15,18] did not ﬁnd any correlation
between metabolite concentrations and the frequency of seizures.
Creatine is a marker for energy metabolism, and possibly
epileptogenic areas may have higher metabolism even at an
inter-ictal state. Another potential explanation for an increase of Cr
in cerebral lesions could be astrogliosis. Some in vitro studies of
cultured neuronal and glial cells [38,39] suggested that the Cr
concentration is higher in astrocytes than in neurons. Elevated Cr
in some studies of patients with multiple sclerosis [40] and inpatients with temporal lobe epilepsy [31] has therefore been
interpreted as an indication of gliosis. In FCDs, gliosis is an
additional feature [5], and balloon cells, hallmark of type IIb FCDs
[2], occasionally are positive for the glial marker GFAP (glial
ﬁbrillary acid protein) [2,5].
Other clinical or imaging features such as the duration of
epilepsy, the post-operative outcome or the size of the lesion did
not correlate with metabolic parameters, which is in accordance
with the literature [12,15,18].
Based on clinical observation and self-reports, patients were
scanned at an inter-ictal state. However, we found lactate in the
FCD lesions of two patients. Accumulation of lactate is usually
reported in the epileptogenic focus during or shortly after seizures
[15]. Lactate signal can increase probably due to either enhanced
glycolysis by alkalotic stimulation of phosphofructokinase or
reduced lactate clearance in the observed tissue volume [15]. We
thus scrutinized the medical histories of the two patients with
increased lactate and realized that patient No. 7 had a complex-
partial seizure six hours before the MRI, whereas patient No. 3 was
seizure-free 36 h prior to the MRI. Thus, in the latter case there was
no clinically apparent or self-reported seizure to explain the
presence of lactate. As FCDs are intrinsically epilptogenic foci, one
might speculate that the presence of lactate could reﬂect this
abnormal activity even in the absence of clinical seizure.
The present study has some limitations: The inter-ictal state
was determined, as done in most studies, according to self-reports
and clinical observations, and not by continuous video-EEG
recordings prior to MRI, giving rise to some uncertainty with
respect to the true inter-ictal state. Considering lactate (see above)
as a seizure-related marker, this uncertainty might be a problem in
one of our patients only. Furthermore, the intra-individual
approach and the contamination of the voxel with perilesional
normal tissue are possible limitations of our study, as the FCD
effects might even be underestimated. Not all patients had
histological conﬁrmation of the FCD. Finally, we did not examine
patients with lesions other than FCDs. Low grade glioma is a
differential diagnosis to FCD in patients with seizures and a focal
lesion [19,26]. Loss of NAA and increase in Cho are shared features.
However, in gliomas, increase in Cho is accompanied by a distinct
reduction of NAA [19,26], while the NAA decrease in FCD was
comparatively less pronounced. Inﬂammatory changes like in
multiple sclerosis show a comparable metabolite pattern with
mild decrease of NAA and increase in Cho [41], but usually this is
not a differential diagnosis on conventional MR imaging.
5. Conclusion
Our results suggest that the spectroscopic detection of
metabolic changes typically linked to FCD may help to differentiate
FCD-suspicious lesions from normal brain tissue with a higher
degree of certainty. The clinical value of this novel approach,
however, has to be tested in further studies investigating more
subtle lesions (i.e. without transmantle sign) with subsequent
histopathological conﬁrmation after resective epilepsy surgery.
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